Mushrooms and Blood Thinners: Interaction Risks

Mushrooms & Drug Interactions

2 mechanisms

Mushrooms can interact with blood thinners through two distinct pathways: direct anticoagulant and antiplatelet activity documented in lab studies, and CYP2C9 enzyme inhibition that can slow warfarin metabolism. Both are in vitro findings. No clinical cases have been confirmed.

Kozarski et al., Molecules, 2019

In vitro

all available platelet and coagulation data. No confirmed clinical interaction cases for functional mushrooms and anticoagulants

4 species

with documented anticoagulant or antiplatelet activity in lab research: reishi, lion's mane, wood ear, and maitake

Warfarin

carries the highest specific concern due to narrow therapeutic window and CYP2C9 metabolism overlap with reishi triterpenoids

Kozarski et al., Molecules, 2019

View as image ↗

People taking anticoagulant or antiplatelet medications face a specific version of the supplement interaction question. "Is it safe to take mushrooms with my blood thinner?" has a more nuanced answer than most supplement sites provide: the concern is mechanistically real, the evidence base is almost entirely in vitro, and the practical significance at typical supplement doses is unknown.

This article covers the two mechanisms by which mushroom compounds can affect blood coagulation and platelet function, which species show the most activity in lab studies, and what that means specifically for people on warfarin, aspirin, or newer anticoagulants. This is part of the broader mushroom drug interactions guide and the mushroom extraction and pharmacology series.

Two Mechanisms That Make This Concern Specific

Most supplement-drug interaction warnings are vague. For mushrooms and blood thinners, the concern has two distinct mechanistic pathways, and distinguishing them matters for understanding which drugs and which mushroom species pose the greatest risk.

Mechanism 1: Direct anticoagulant and antiplatelet activity. Several mushroom species contain compounds that directly inhibit platelet aggregation (the clumping process that forms clots) or inhibit thrombin (the enzyme that converts fibrinogen to fibrin, the structural component of clots). This adds an anticoagulant effect on top of whatever drug a patient is already taking.

Mechanism 2: CYP2C9 inhibition affecting warfarin metabolism. Warfarin is primarily metabolized by the liver enzyme CYP2C9. If reishi triterpenoids inhibit CYP2C9 (as in vitro data suggests), warfarin is cleared more slowly and accumulates to higher blood levels. This is a pharmacokinetic interaction rather than a pharmacodynamic one: the issue is not that both substances thin the blood, but that one prevents the other from being cleared.

The reason warfarin specifically attracts the most concern from clinicians is that it has a narrow therapeutic window. Small increases in warfarin blood levels can tip a patient from therapeutic to bleeding risk. The INR (international normalized ratio) monitoring that warfarin patients undergo is designed precisely because even minor disruptions to warfarin metabolism can have consequences.

For the CYP2C9 data specifically, see Mushrooms and Cytochrome P450: Do They Affect Drug Metabolism?.

Which Species Show the Most Anticoagulant Activity in Lab Studies

Kozarski and colleagues conducted one of the most systematic in vitro assessments of mushroom effects on human platelet function and blood coagulation across multiple species.^[1]

Reishi (Ganoderma lucidum) extracts inhibited platelet aggregation in the assay. Lion's mane (Hericium erinaceus) also inhibited platelet aggregation. The magnitude of inhibition was species-dependent and extract-type-dependent: whether the extract was water-based or alcohol-based affected the result, which matters because consumers use different product forms.

Two important qualifications from this data: the findings are in vitro using isolated human platelets in lab conditions, not in whole blood in a living person. And the concentrations used in platelet assays are often higher than what circulates in human blood after typical supplement dosing. These are mechanistic data points, not clinical predictions.

A 2018 comprehensive review of mushroom cardiovascular research confirmed that antiplatelet and anticoagulant activities are found across multiple mushroom species, documented in the context of their potential effects on atherosclerosis.^[3] This cross-species breadth is relevant: the interaction concern is not limited to reishi or lion's mane. Consumers who rotate between different mushroom products, or take combination blends, are potentially exposed to multiple species with overlapping anticoagulant activities.

A Natural Standard systematic review of maitake (Grifola frondosa) explicitly noted drug interaction potential with blood thinners based on the animal and in vitro evidence base.^[4] The review noted insufficient human clinical evidence to establish safety margins, which is the honest statement for this entire topic.

For detailed coverage of the anticoagulant and antiplatelet biology itself, see Mushrooms and Blood Clotting: Anticoagulant and Antiplatelet Research and Mushrooms and Blood Thinners: Drug Interactions You Need to Know.

Auricularia's Antithrombin Mechanism: The Most Specific Data

The most structurally specific anticoagulant mechanism documented in any mushroom species involves Auricularia auricula, the wood ear mushroom commonly used in Asian cooking.

Yue and colleagues characterized a water-soluble polysaccharide from Auricularia auricula that inhibited thrombin activity via the antithrombin pathway in vitro.^[2] The antithrombin mechanism is the same pathway through which heparin, a clinical anticoagulant, exerts its effect. The Auricularia polysaccharide enhanced antithrombin activity, reducing thrombin's ability to convert fibrinogen to fibrin.

The polysaccharide is water-soluble and heat-stable, meaning it survives cooking. This is relevant because Auricularia is primarily a food mushroom rather than a supplement. People eating wood ear mushrooms regularly, not just supplementing, are consuming this polysaccharide in whatever concentrations the mushroom provides.

The in vitro nature of this finding applies here too: antithrombin enhancement in isolated clotting assays does not directly predict the magnitude of anticoagulant effect in a person taking it alongside warfarin. But the mechanism is specific enough that it warrants noting for patients on anticoagulants who eat wood ear mushrooms as a regular dietary component.

What This Means by Drug Type

The practical concern differs significantly depending on which anticoagulant medication is involved.

Warfarin (Coumadin): The highest specific concern among anticoagulants. Two overlapping mechanisms: direct anticoagulant/antiplatelet activity from multiple mushroom species, plus potential CYP2C9-mediated slowing of warfarin metabolism from reishi triterpenoids. Warfarin's narrow therapeutic window means even modest pharmacokinetic interactions can push INR out of range. Patients on warfarin who take INR-monitored coagulation therapy have the most to lose from unexpected interactions.

Aspirin (low-dose antiplatelet therapy): Aspirin works by permanently inhibiting COX-1 in platelets, preventing thromboxane A2 production. Adding a second antiplatelet agent from mushrooms creates additive antiplatelet load. The clinical consequences at typical mushroom supplement doses are unknown, but the directional concern is real. Aspirin-mushroom combinations are likely among the most common interactions occurring in consumers, given the widespread use of low-dose aspirin for cardiovascular prevention.

Clopidogrel (Plavix) and similar P2Y12 inhibitors: These inhibit a different platelet receptor (ADP receptor P2Y12). The interaction with mushroom antiplatelet compounds that work via different pathways (collagen-induced aggregation, thrombin pathway) could be additive through distinct mechanisms. Less specific data exists for this drug class and mushrooms.

Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran): These are metabolized by CYP3A4 and P-glycoprotein rather than CYP2C9. The CYP2C9-focused warfarin concern does not apply identically here. However, the direct antiplatelet activity of mushroom species remains a concern regardless of which anticoagulant class is used.

The Evidence Gap and What It Means Practically

No clinical study has measured INR changes, bleeding time, or bleeding events in people taking functional mushroom supplements alongside anticoagulant medications. The absence of such data is itself a data point: the interaction concern exists at the mechanistic level, and no clinical study has been done to confirm or refute it.

For patients on warfarin specifically, the relevant practical question is whether they should tell their prescriber they are taking mushroom supplements. Given that warfarin is monitored via regular INR testing and that any change in INR-affecting compounds typically triggers a monitoring discussion, informing the prescriber allows the monitoring to catch any actual effect if it occurs.

For patients on aspirin, the threshold for concern is lower because aspirin does not require narrow-window monitoring. The additive antiplatelet concern exists but has no clinical evidence of harm at supplement doses.

For patients on DOACs, the interaction profile is less characterized. These drugs generally have fewer food and supplement interactions than warfarin, but the direct antiplatelet activity of mushrooms remains a theoretical concern.

For additional context on the safety profile of specific mushroom species, see Cordyceps Side Effects: What the Safety Research Shows.

The Bottom Line

Mushrooms interact with blood thinners through two mechanisms: direct anticoagulant and antiplatelet activity confirmed in vitro across multiple species, and CYP2C9 inhibition by reishi triterpenoids that could slow warfarin metabolism. The in vitro evidence is real and mechanistically specific. The clinical significance at supplement doses is unknown because no clinical studies have measured these effects in humans taking both. Warfarin carries the highest specific concern due to its narrow therapeutic window and the CYP2C9 overlap. The evidence base does not establish that mushroom supplements are unsafe with blood thinners, but it provides a coherent mechanistic reason why the combination warrants awareness, particularly for patients on INR-monitored warfarin therapy.

Frequently Asked Questions

Can I take reishi if I'm on warfarin?

Reishi has the highest interaction concern among mushroom species for warfarin patients for two reasons. First, reishi extracts inhibited platelet aggregation in a multi-species in vitro study.^[1] Second, reishi triterpenoids inhibit CYP2C9 in vitro, and warfarin is primarily metabolized by CYP2C9. Reishi could slow warfarin clearance and raise its blood levels. No clinical study has confirmed this interaction in humans, but warfarin's narrow therapeutic window makes even theoretical interactions worth monitoring.

Do mushrooms thin the blood?

Several mushroom species inhibit platelet aggregation or coagulation in laboratory studies. Reishi, lion's mane, and Auricularia (wood ear) all have documented anticoagulant or antiplatelet activity in vitro.^[1][2] Whether this translates to meaningful blood-thinning effects in people at normal dietary or supplement doses has not been measured in clinical studies. The in vitro mechanisms are real; the clinical magnitude is unknown.

Which mushrooms are anticoagulant?

Based on the available in vitro evidence: reishi and lion's mane inhibit platelet aggregation in human platelet assays.^[1] Auricularia auricula (wood ear) contains a polysaccharide that inhibits thrombin via the antithrombin pathway.^[2] Maitake has been flagged in systematic reviews as having potential blood-thinning drug interactions based on animal and in vitro data.^[4] A broader cardiovascular review confirmed antiplatelet and anticoagulant activities across multiple species.^[3]

Can mushrooms increase bleeding risk?

Theoretically, yes, through additive anticoagulant and antiplatelet effects on top of existing blood thinner medications. The practical risk at supplement doses has not been quantified in clinical studies. People already on anticoagulants (especially warfarin) or antiplatelet drugs (aspirin, clopidogrel) represent the population where the concern is most relevant, because they already have reduced clotting capacity and any additional anticoagulant load could push the balance further.

Is it safe to take lion's mane with aspirin?

Lion's mane inhibited platelet aggregation in vitro in a multi-species study.^[1] Aspirin also inhibits platelet function through a different mechanism (COX-1 inhibition). The combination creates two antiplatelet agents working through distinct pathways. No clinical study has measured this combination in humans. The directional concern is additive antiplatelet load, which is real but has unknown clinical magnitude at typical lion's mane supplement doses.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4RTHM-00319·Ulbricht, Catherine et al. (2009). “Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration..” Journal of the Society for Integrative Oncology.Study breakdown →PubMed →↩